Patents Assigned to Dyax Corporation
-
Patent number: 9403910Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.Type: GrantFiled: March 14, 2013Date of Patent: August 2, 2016Assignees: Acceleron Pharma Inc., Dyax CorporationInventors: Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
-
Patent number: 9359438Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.Type: GrantFiled: June 1, 2012Date of Patent: June 7, 2016Assignee: DYAX CORPORATIONInventors: Daniel J. Sexton, Christopher Tenhoor, Malini Viswanathan
-
Patent number: 8058016Abstract: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.Type: GrantFiled: September 8, 2009Date of Patent: November 15, 2011Assignees: Astrazeneca AB, Dyax CorporationInventors: Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, René Hoet, Henricus Hoogenboom, Simon Hufton, Christin V. Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov
-
Patent number: 7854919Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.Type: GrantFiled: January 19, 2007Date of Patent: December 21, 2010Assignees: Bracco, Suisse SA, Dyax CorporationInventors: Christophe Arbogast, Philippe Bussat, Hong Fan, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian Nunn, Radhakrishna Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Aaron Sato, Sharon Michele Walker, Daniel T. Dransfield, Ajay Shrivastava
-
Publication number: 20100061993Abstract: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.Type: ApplicationFiled: September 8, 2009Publication date: March 11, 2010Applicants: ASTRAZENECA AB, DYAX CORPORATIONInventors: Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, René Hoet, Henricus Hoogenboom, Simon Hufton, Christin V. Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov
-
Patent number: 7612179Abstract: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.Type: GrantFiled: November 26, 2004Date of Patent: November 3, 2009Assignees: Astrazeneca AB, Dyax CorporationInventors: Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, René Hoet, Henricus Hoogenboom, Simon Hufton, Christin V. Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov
-
Publication number: 20070243139Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.Type: ApplicationFiled: January 19, 2007Publication date: October 18, 2007Applicants: BRACCO INTERNATIONAL B.V., DYAX CORPORATIONInventors: Christophe Arbogast, Philippe Bussat, Hong Fan, Karen Linder, Edmund Marinelli, Palaniappa Nanjappan, Adrian Nunn, Radhakrishna Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf Swenson, Mathew Von Wronski, Aaron Sato, Sharon Walker, Daniel Dransfield
-
Publication number: 20070172428Abstract: The invention provides compositions and methods for therapeutic and diagnostic applications.Type: ApplicationFiled: March 21, 2007Publication date: July 26, 2007Applicants: BRACCO INTERNATIONAL B.V., DYAX CORPORATIONInventors: Christophe Arbogast, Philippe Bussat, Hong Fan, Karen Linder, Edmund Marinelli, Palaniappa Nanjappan, Adrian Nunn, Radhakrishna Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf Swenson, Mathew Von Wronski, Aaron Sato, Sharon Walker, Daniel Dransfield
-
Patent number: 7235530Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.Type: GrantFiled: May 9, 2005Date of Patent: June 26, 2007Assignee: Dyax CorporationInventors: Henry Blair, Thomas Beck, Robert C. Ladner
-
Publication number: 20070049522Abstract: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.Type: ApplicationFiled: August 24, 2006Publication date: March 1, 2007Applicant: DYAX CORPORATION*EWC*Inventors: Robert Ladner, Arthur Ley, Shirish Hirani, Anthony Williams, Maria De Simoni, Luigi Bergamaschini
-
Publication number: 20050100963Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.Type: ApplicationFiled: September 11, 2003Publication date: May 12, 2005Applicants: Dyax CorporationInventors: Aaron Sato, Daniel Sexton, Daniel Dransfield, Robert Ladner, Christophe Arbogast, Philippe Bussat, Hong Fan, Sudha Khurana, Karen Linder, Edmund Marinelli, Palaniappa Nanjappan, Adrian Nunn, Radhakrishna Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf Swenson, Mathew Von Wronski
-
Publication number: 20040180327Abstract: Disclosed are methods for identifying desired members from a display libraries, including bacteriophage display libraries. Display library members can be amplified in the presence of a target compound so that cycles of selection can be rapidly completed.Type: ApplicationFiled: September 5, 2003Publication date: September 16, 2004Applicant: DYAX CORPORATIONInventors: Robert C. Ladner, Shannon Hogan, Kristin Rookey
-
Publication number: 20040110933Abstract: The invention provides, inter alia, CD44-binding proteins, including CD4-binding antibodies, antibody fragments, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such proteins. Methods of using the proteins to detect CD44 or to modulate a CD44-expressing cell, e.g., in a subject, are also described.Type: ApplicationFiled: September 15, 2003Publication date: June 10, 2004Applicant: DYAX CORPORATIONInventors: Isaac J. Rondon, Albert Edge, Rachel Baribault Kent
-
Publication number: 20040071705Abstract: Disclosed is an artificial target-specific ligand that binds to both serum albumin and a particular molecular target. Interaction with serum albumin improves properties when administered to a subject. For example, an interaction between the ligand and serum albumin can extend the half-life of the ligand in circulation.Type: ApplicationFiled: June 23, 2003Publication date: April 15, 2004Applicant: DYAX CORPORATIONInventors: Aaron K. Sato, Albert Edge
-
Publication number: 20040009534Abstract: Disclosed, inter alia, is a method of evaluating a sample that includes a serum protein and one or more one or more compounds physically associated with the serum protein. The method can include using a peptide ligand that specifically interacts with the serum protein to analyze a complex formed by the serum protein and its associated compounds.Type: ApplicationFiled: June 16, 2003Publication date: January 15, 2004Applicant: DYAX CORPORATIONInventors: Aaron K. Sato, Bruce M. Dawson
-
Publication number: 20030235868Abstract: Antibodies and peptide ligands are described herein, which are specific for epitopes on MUC-H, which reside on the MUC1 extracellular fragment remaining on the cell surface after cleavage of the MUC1 protein.Type: ApplicationFiled: April 16, 2003Publication date: December 25, 2003Applicant: DYAX CorporationInventors: Hendricus R.J.M. Hoogenboom, Maria Paulina Godelieve, Albert S.B. Edge
-
Publication number: 20030232395Abstract: The invention provides, inter alia, a method of preparing a nucleic acid sequence that encodes a polypeptide that is displayed on a heterologous cell surface. The generally includes recombining a donor nucleic acid and an acceptor nucleic acid to form a recombined nucleic acid that encodes a polypeptide that is displayed. The recombination reaction is typically an in vivo reaction, in that at least the resolution of recombination intermediates occurs within a cell. Both site-specific recombination and homologous recombination can be used.Type: ApplicationFiled: June 16, 2003Publication date: December 18, 2003Applicant: DYAX CORPORATIONInventor: Simon E. Hufton
-
Publication number: 20030224408Abstract: Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells.Type: ApplicationFiled: March 7, 2003Publication date: December 4, 2003Applicant: DYAX CORPORATIONInventors: Henricus Renerus Jacobus Mattheus Hoogenboom, Jurgen Mullberg, Robert C. Ladner
-
Patent number: 6629626Abstract: A device for transferring small drops of liquid from one or more liquid holders to one or more liquid destinations is disclosed. The device includes a support member and a plurality of fluid transfer members extending from the support member. Each fluid transfer member includes a flexible liquid transfer end.Type: GrantFiled: March 7, 2000Date of Patent: October 7, 2003Assignee: Dyax, CorporationInventors: Jeffrey A. Horsman, Ivan Hargro, Peter Rahn
-
Publication number: 20030157091Abstract: Disclosed are compositions and methods to generate functional target-binding proteins from at least two separate polypeptide chains, one including the target-binding domain, the other including an effector domain. For example, the two separate chains are reconstituted as a functional protein by a non-covalent binding interaction mediated by an interaction sequence or by intein-mediated ligation.Type: ApplicationFiled: February 11, 2003Publication date: August 21, 2003Applicant: DYAX CORPORATIONInventor: Henricus Renerus Jacobus Mattheus Hoogenboom